secwatch.observer — SEC 8-K summary
======================================

Issuer:     UroGen Pharma Ltd. (URGN)
CIK:        0001668243
Form:       8-K
Filed at:   2022-09-12T23:59:59+00:00
Accession:  0001437749-22-022160
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

UroGen appoints Dr. Leana Wen to board and audit committee
----------------------------------------------------------

- Dr. Wen appointed to fill vacancy; term runs until 2023 annual meeting.
- Received initial option for 20,000 ordinary shares vesting quarterly over 12 quarters.
- Annual retainer of $40,000 for board service plus $7,500 for audit committee.
- Eligible for annual option grant of 10,000 ordinary shares at each shareholder meeting.
- Company entered standard director indemnity agreement with Dr. Wen.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1668243/000143774922022160/0001437749-22-022160-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1668243/000143774922022160/urgn20220909_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-022160

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer